Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03044431 · ClinicalTrials.gov registry record

Autologous Stem Cell Treatment for Chronic Lung Disease Study

A clinical trial of COPD and Interstitial Lung Disease, sponsored by Lung Institute.

Completed
Registry status
207
Enrollment target
1
Study location

NCT03044431: Completed study of COPD and Interstitial Lung Disease, sponsored by Lung Institute.

NCT03044431 is a study of COPD and Interstitial Lung Disease that has completed, run by Lung Institute. The registered enrollment target is 207 participants, below the 2,416-participant average among 85 other COPD trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03044431, a study of COPD and Interstitial Lung Disease, has completed, sponsored by Lung Institute.

COMPLETED
Registry status
207 participants
Enrollment target
1
Study location

Study Summary

The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day. Lung Institute's treatment is limited to self-funded patients with chronic lung disease- chronic obstructive pulmonary disease (COPD) and restrictive lung diseases such as pulmonary fibrosis (PF) and interstitial lung disease (ILD). The patient's cells and platelet rich plasma are harvested through venous or bone marrow collection techniques. The hypothesized outcomes of therapy are safety and minimization of adverse events, a perceived improvement in the patient's lung condition (to be determined by their perceived quality of life), an improvement in the FEV1 among COPD patients, the ability to reduce supplemental oxygen use, the ability to function well without the use of rescue inhalers, reduction of secondary pulmonary infections, reduction in emergency room visits and exacerbations related to their disease.

Primary Outcome

Change from baseline (among COPD patients only) as measured by pulmonary function testing/spirometry at baseline and again at 6 months post- treatment

Interventions

  • PROCEDURE Cell therapy

Study Locations (1)

Texas

  • Lung Institute Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 207 participants
Start Date 2016-04-01
Est. Completion 2017-06-09
Lung Institute

2 total trials

What the finished NCT03044431 record still lists

NCT03044431 is an observational study that tracks outcomes without assigning an intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 2,416-participant average among 85 other COPD trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with COPD appearing as the primary indexed condition, and to 1 intervention - of which Cell therapy is the first listed.

NCT03044431 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03044431 about?

NCT03044431 is a clinical study titled "Autologous Stem Cell Treatment for Chronic Lung Disease Study". The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day. Lung Institute's treatment is limited to self-funded patients with chronic lung disease- chronic obstructive pulmonary disease (C...

What is the current status of trial NCT03044431?

This trial is currently completed. The enrollment target is 207 participants. The study started on 2016-04-01. Estimated completion is 2017-06-09.

What conditions does trial NCT03044431 study?

This clinical trial studies the following conditions: COPD, Interstitial Lung Disease.

What interventions are being tested in trial NCT03044431?

The interventions under investigation include: Cell therapy (PROCEDURE).

Who is sponsoring clinical trial NCT03044431?

This trial is sponsored by Lung Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03044431 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03044431's enrollment target sits among peer trials

207 29th of 85 higher than 57 of 85 other COPD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04353778 · 207 participants · Phase 1

    Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

  • NCT05875805 · 207 participants · NA

    A Telehealth Advance Care Planning Intervention

  • NCT06254950 · 207 participants · Phase 2

    A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  • NCT06904274 · 207 participants · Phase 3

    Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03044431, the US trial registry maintained by the National Library of Medicine. NCT03044431 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.